Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion
- 1 September 2006
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 66 (12), 1311-1318
- https://doi.org/10.1002/pros.20464
Abstract
Monocyte chemotactic protein-1 (MCP-1) plays a key role in the recruitment and activation of monocytes during inflammation. Increased MCP-1 serum levels in patients with various cancers were correlated with advanced stage. Here, we evaluated the role of MCP-1 on prostate cancer (CaP) cell proliferation and invasion. Expression of MCP-1 in tissue specimens was analyzed by immunohistochemical staining. MCP-1 production was determined by ELISA in conditioned media collected from primary prostate epithelia (PrEC), LNCaP, C4-2B, PC3 cells, and hFOB. Cell proliferation and invasion were assayed by MTS assay and invasion chambers. All CaP cells, as well as hFOB, produced high amount of MCP-1 compared to PrEC cells. MCP-1 expression levels were associated with advanced pathologic stage. MCP-1 induced proliferation and invasion of CaP cells and this was abolished partially either by CCR2 antagonist or PI3 Kinase inhibitor. MCP-1 acts as a paracrine and autocrine factor for CaP growth and invasion.Keywords
This publication has 32 references indexed in Scilit:
- Expression of CCL5 (RANTES) and CCR5 in prostate cancerThe Prostate, 2005
- Androgen-Independent Prostate Cancer Is a Heterogeneous Group of DiseasesCancer Research, 2004
- CCR5 Expression Influences the Progression of Human Breast Cancer in a p53-dependent MannerThe Journal of Experimental Medicine, 2003
- Inflammation and cancerNature, 2002
- Chemokine receptorsCytokine & Growth Factor Reviews, 2001
- Serum Cytokine Concentrations in Patients with Cervical Cancer: Interleukin-4, Interferon-γ, and Monocyte Chemoattractant Protein-1: To the EditorGynecologic Oncology, 2001
- Cancer Statistics, 2001CA: A Cancer Journal for Clinicians, 2001
- CXC-chemokines stimulate invasion and chemotaxis in prostate carcinoma cells through the CXCR2 receptorThe Prostate, 1999
- Distinct CXC Chemokines Mediate Tumorigenicity of Prostate Cancer CellsThe American Journal of Pathology, 1999
- MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein BJCI Insight, 1999